Inhibitory effects of OK-432 (Picibanil) on cellular proliferation and adhesive capacity of breast carcinoma cells

Oncology Reports

Volumn 13, Issue 2, 2005, Pages 289-294

  Horii, Yoshio ^a   Iino, Yuichi ^a   Maemura, Michio ^a   Horiguchi, Jun ^a   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Breast cancer; Cell adhesion; Integrin; OK 432 (Picibanil)

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; PICIBANIL;

ARTICLE; BREAST TUMOR; CELL ADHESION; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECT; FEMALE; HUMAN; NEOPLASM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL ADHESION; CELL PROLIFERATION; ESTROGENS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PICIBANIL; TUMOR CELLS, CULTURED;

EID: 16244381768     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Blood CH and Zetter BR: Tumor interactions with the vasculature: angionesis and tumor metastasis. Biochim Biophys Acta 1032: 89-118, 1990.
2. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991. (Pubitemid 121001258)
3. Auerbach R: Patterns of tumor metastasis: organ selectivity in the spread of cancer cells. Lab Invest 58: 361-364, 1988.
4. McCormick BA and Zetter BR: Adhesion interactions in angiogenesis and metastasis. Pharmacol Ther 53: 239-260, 1992.
5. Liotta LA: Tumor invasion and metastases - role of the extracellular matrix: Rhoads memorial award lecture. Cancer Res 46: 1-7, 1986.
6. Albelda SM and Buck CA: Integrins and other cell adhesion molecules. FASEB J 4: 2868-2880, 1990. (Pubitemid 120012533)
7. Ruoslahti E: Integrins. J Clin Invest 87: 1-5, 1991.
8. Hynes RO: Integrins: versatility, moduration, and signaling in cell adhesion. Cell 69: 11-25, 1992.
9. Hynes RO: Integrins: a family of cell surface receptors. Cell 48: 549-554, 1987.
10. Danen EHJ, van Muijen GNP, van de Wiel-van Kemenade E, Jansen KFJ, Ruiter DJ and Figdor CG: Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells. Int J Cancer 54: 315-321, 1993. (Pubitemid 23154900)
11. Yanagawa T, Oguro M, Takagi T and Takenaga K: Direct antitumor activity of biological response modifiers (B.R.M.) proven by an in vitro sensitivity test. Jpn J Cancer Chemother (in Japanese with English abstract) 11: 2155-2162, 1984. (Pubitemid 14019376)
12. Okamoto H, Shoin S, Koshimura S and Shimizu R: Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 11: 323-336, 1967.
13. Okamoto H, Minami M, Shoin S, Koshimura S and Shimizu R: Experimental anticancer studies. Part XXXI. On the streptococcal preparation having potent anticancet activity. Jpn J Exp Med 36: 175-186, 1966.
14. Saito M, Yamaguchi T, Ebina T, Koi M, Aonuma E, Usami H and Ishida N: In vitro production of immune interferon (IFN γ) by murine spleen cells when different sensitizing antigens are used in vivo and in vitro. Cell Immunol 78: 379-386, 1983. (Pubitemid 13107894)
15. Saito M, Ebina T, Koi M, Yamaguchi T, Kawade Y and Ishida N: Induction of interferon-γ in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cell Immunol 68: 187-192, 1982. (Pubitemid 12105301)
16. Bonavida B, Katz J and Hoshino T: Mechanism of NK activation by OK-432 (Streptococcus pyogenes). I. Spontaneous release of NKCF and augmentation of NKCF production following stimulation with NK target cells. Cell Immunol 102: 126-135, 1986. (Pubitemid 16031743)
17. Ichimura O, Suzuki S, Saito M, Sugawara Y and Ishida N: Augmentation of interleukin 1 and interleukin 2 production by OK-432. Int J Immunopharmocol 7: 263-270, 1985. (Pubitemid 15075829)
18. Aiba S and Tagami H: Proliferative responses of peripheral blood mononuclear cells from psoriatic patients to T lymphocyte-stimulating cytokines (IL-2, 1L-3, IL-4, and granulocyte-macrophage colony-stimulating factor) and OK-432. Arch Dermatol Res 281: 310-315, 1989. (Pubitemid 19222013)
19. Fukui H, Koishihara Y, Nagamuta M, Mizutani Y and Uchida A: Production of interleukin 6 by human spleen cells stimulated with streptococcal preparation OK-432. Immunol Lett 21: 127-130, 1989. (Pubitemid 19135904)
20. Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y and Urushizaki I: Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Immunopharmacology 11: 79-86, 1986. (Pubitemid 16145273)
21. Chirigos MA, Saito T, Talmadge JE, Budzynski W and Gruys E: Cell regulatory and immunorestorative activity of picibanil (OK-432). Cancer Detect Prev 1 (Suppl): 317-328, 1987.
22. Uchida A, Micksche M and Hoshino T: Intrapleural administration of OK-432 in cancer patients: Augmentation of autologous tumor-killing activity of tumor-associated large granular lymphocytes. Cancer Immunol Immunother 18: 5-12, 1984. (Pubitemid 14017313)
23. Uchida A and Micksche M: Suppressor cells for natural killer activity in carcinomatous pleural effusions of cancer patients. Cancer Immunol Immunother 11: 255-263, 1981. (Pubitemid 11027693)
24. Iino Y, Ogawa T, Yoshida M, Izuo M and Takikawa H: Effects of OK-432 (Picibanil) on estrogen receptor levels and tamoxifen treatment in 7,12-dimethylbenz[a] anthracene-induced rat mammary cancers. Oncology 47: 185-190, 1990. (Pubitemid 20075561)
25. Aoyagi H, Iino Y, Takeo T, Horii Y, Morishita Y and Horiuchi R: Effects of OK-432 (Picibanil) on the estrogen receptors of MCF-7 cells and potentiation of antiproliferative effects of tamoxifen in combination with OK-432. Oncology 54: 414-423, 1997. (Pubitemid 27321121)
26. Akiyama SK, Yamada SS, Chen W-T and Yamada KM: Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization. J Cell Biol 109: 863-875, 1989. (Pubitemid 19197044)
27. Hinegardner RT: An improved fluorometric assay for DNA. Anal Biochem 39: 197-201, 1971.
28. Thompson EW, Brüner N, Torii J, Johnson MD, Boulay V, Wright A, Lippman ME, Steeg PS and Clarke R: The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis 11: 15-26, 1993. (Pubitemid 23045686)
29. Torisu M, Katano M, Kimura Y, Itoh H and Takesue M: New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93: 357-364, 1983. (Pubitemid 13086972)
30. Katano M and Torisu M: New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery 93: 365-373, 1983. (Pubitemid 13086973)
31. Kitahara S, Ikeda M, Inoue T, Matsunaga T, Yamaguchi K, Takayama E, Healy GB and Tsukuda M: Inhibition of head and neck metastasis and/or recurrent cancer by local administration of multi-cytokine inducer OK-432. J Laryngol Otol 110: 449-453, 1996.
32. Nio Y, Nagami H, Tamura K, Tsubono M, Nio M, Sato M, Kawabata K, Hayashi H, Shiraishi T, Imai S, Tsuchitani T, Mizuta J, Nakagawa M and Fukumoto M: Multi-institutional randomized clinical study on the comparative effects of intra-cavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br J Cancer 80: 775-785, 1999. (Pubitemid 29209840)
33. Amano M, Sekimoto M, Monden T, Tomita N, Ohue M, Haba A, Sakita I, Tamaki Y and Monden M: Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen. Dis Colon Rectum 43: 402-407, 2000. (Pubitemid 30158579)
34. Uehara T, Yano T, Kuninaka S, Yoshino I, Asoh H and Ichinose Y: The influence of enhanced postoperative inflammation by the intrapleural administration of streptococcal preparation (OK-432) on the prognosis of completely resected non-small cell lung cancer. J Surg Oncol 75: 51-54, 2000.
35. Yoshida T, Sakon M, Umeshita K, Kanai T, Miyamoto A, Takeda T, Gotoh M, Nakamura H, Wakasa K and Monden M: Appraisal of transarterial immunoembolization for hepatocellular carcinoma: a clinocopathologic stude. J Clin Gastroentol 32: 59-65, 2001. (Pubitemid 32038114)
36. Gochi A, Orita K, Fuchimoto S, Tanaka N and Ogawa N: The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer 84: 443-451, 2001. (Pubitemid 32215867)
37. Sakamoto J, Teramukai S, Watanabe Y, Hayata Y, Okayasu T, Nakazato H and Ohashi Y: Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with respected non-small cell lung cancer. J Immunother 24: 250-256, 2001. (Pubitemid 32479716)
38. Fujimoto T, Zhang B, Minami S, Wang X, Takahashi Y and Mai M: Evaluation of intraoperative intraperitoneal cytology for advanced gastric carcinoma. Oncology 62: 201-208, 2002. (Pubitemid 34639052)
39. Sakamoto J, Teramukai S, Nakazato H, Sato Y, Uchino J, Taguchi T, Ryoma Y and Ohashi Y: Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother 25: 405-412, 2002.
40. Shibata M, Nezu T, Fujisaki S, Andou K, Tomita R and Fukuzawa M: Clinical potential of biological response modifiers combined with chemotherapy for gastric cancer. Japanese experience. Dis Surg 19: 255-260, 2002. (Pubitemid 35013723)
41. Albelda SM: Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 68: 4-17, 1993.
42. Maemura M and Dickson RB: Are cellular adhesion molecules involved in the metastasis of breast cancer? Breast Cancer Res Treat 32: 239-260, 1994.
43. Terranova VP, Hujanen ES and Mratin GR: Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer 77: 311-316, 1986. (Pubitemid 16039378)
44. Kirchhofer D, Languino LR, Ruoslahti E and Pierschbacher MD: α2β1 Integrins from different cell types show different bindings specificities. J Biol Chem 265: 615-618, 1990.
45. Maemura M, Akiyama SK, Woods VL Jr and Dickson RB: Expression and ligand binding of α2β1 integrin on breast carcinoma cells. Clin Exp Metastasis 13: 223-235, 1995.
46. Santala P and Heino J: Regulation of integrin-type cell adhesion receptors by cytokines. J Biol Chem 266: 23505-23509, 1991. (Pubitemid 21908823)
47. Chan BMC, Matsuura N, Takada Y, Zetter BR and Hemler ME: In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science 251: 1600-1602, 1991. (Pubitemid 21916931)
48. Cooper HM, Tamura RN and Quaranta V: The major laminin receptor of mouse embryonic stem cells in a novel isoform of the α6β1 integrin. J Cell Biol 115: 843-850, 1991. (Pubitemid 21909935)
49. Shaw LM, Messier JM and Mercurio AM: The activation dependent adhesion of macrophages to laminin involves cytoskeletal anchoring and phosphorylation of the α6β1 integrin. J Cell Biol 110: 2167-2174, 1990.
50. Zheng M, Fang H and Hakomori S: Functional role of N-glycosylation in α5β1 integrin receptor. De-N-glycosylation induces dissociation or altered association of α5 and β1 subunits and concomitant loss of fibronectin binding activity. J Biol Chem 269: 12325-12331, 1994.